STOCKHOLM, June 15, 2018 /PRNewswire/ --
Chemoimmunotherapy (R-chemo) induction followed by rituximab maintenanceis the standard of care in previously untreated, symptomatic follicular lymphoma (FL). Lenalidomide is an immunomodulatory agent with complementary mechanisms when combined with rituximab (ie, R2). RELEVANCE is the first randomized phase III superiority
(Logo: http://mma.prnewswire.com/media/622259/EHA_Logo.jpg )
Presenter: Dr Frank Morschhauser
Affiliation: Centre Hospitalier Universitaire Régional de Lille, Unité GRITA, Lille, France
Topic: RELEVANCE: PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
Abstract S154 will be presented by Frank Morschhauser on Friday, June 15, 17:00-17:15 in Room A1.
Please note that our embargo policy applies to all selected abstracts in the Press Briefings. For more information check our Congress Media Guidelines here.
SOURCE European Hematology Association
Subscribe to our Free Newsletters!
Necrotizing fasciitis is a rare life threatening bacterial infection of the tissue below the skin ...
Menstruation or period is the discharge of blood and mucus called menses from the uterus via the ...
Chronic dieting is associated with eating disorders that mainly include unhealthy eating practices ...View All